New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:01 EDTTEVATeva, OncoGenex say Phase III SYNERGY trial did not meet primary endpoint
Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer. Top-line survival results indicate the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic CRPC, compared to docetaxel/prednisone alone. We are disappointed with these results. Addressing treatment resistance is critical in the fight against cancer. We are working with OncoGenex to more fully understand these data, said Michael Hayden, MD, president of global R&D and chief scientific officer at Teva Pharmaceutical Industries Ltd. The adverse events observed for custirsen were similar to its known AE profile.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:28 EDTTEVASenate Health, Education, Labor & Pensions Committee to hold a hearing
The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link
07:42 EDTTEVAIntellipharmaceutics notes launch of 5mg strength Focalin XR by Teva
Subscribe for More Information
November 18, 2014
11:22 EDTTEVATeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
10:08 EDTTEVATeva calls active on renewed takeover chatter
Teva November 57 and 58 calls are active on total call volume of 21K contracts (2K puts) following renewed takeover chatter. November call option implied volatility is at 18, December is at 19; compared to its 26-week average of 24 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:47 EDTTEVARumor: Teva moves up on renewed takeover chatter
Subscribe for More Information
08:00 EDTTEVATeva launches liquid formulation of TREANDA injection in the U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use